Workhorse Highlights Achievements in 2023 Year-End Letter to Shareholders
CINCINNATI, Dec. 21, 2023 (GLOBE NEWSWIRE) — Workhorse Group Inc. (Nasdaq: WKHS) (“Workhorse” or “the Company”), an American technology company […]
IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial
NEW YORK, Dec. 21, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating […]
DMK Pharmaceuticals Regains Full Rights to Commercialize ZIMHI
SAN DIEGO, Dec. 21, 2023 (GLOBE NEWSWIRE) — DMK Pharmaceuticals Corporation (Nasdaq: DMK) (“DMK”), a commercial stage neuro-biotech company primarily […]
SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas
– SLS009 Demonstrated Promising Efficacy in Phase 1 Study with 36.4% Clinical Response (ORR) in r/r Peripheral T-cell Lymphomas (PTCL); […]
NFT Gaming Company Launches Artificial Intelligence (AI) Game, Jigsaw Puzzle AI, on Apple and Google Play
Roseland, NJ, Dec. 21, 2023 (GLOBE NEWSWIRE) — The NFT Gaming Company, Inc. (“NFTG” or the “Company”), a company developing […]
Snail., Inc Unveils Everlasting Winter Wonderland Mod For ARK: Survival Ascended
CULVER CITY, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) — Snail, Inc. (Nasdaq: SNAL) (“Snail” or “the Company”), a leading, global […]
Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Media Release SYDNEY, AUSTRALIA, Dec. 21, 2023 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), […]
PetVivo Holdings, Inc. Achieves Distribution Milestone Surpassing 4500 Syringes of Spryng™ in 2023
MINNEAPOLIS, MN, US, Dec. 21, 2023 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company”), an emerging […]
Clover Health Announces Departure of Chief Financial Officer; Reiterates Most Recently Issued Financial Guidance for 2023
FRANKLIN, Tenn., Dec. 21, 2023 (GLOBE NEWSWIRE) — Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover” or the “Company”) a physician […]
BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer
Designation is based on Phase 1/2 safety and efficacy data in patients with Human Epidermal Growth Factor Receptor 2 (“HER2”)-expressing […]
